Media Center

PRESS RELEASE 2011

REGULATORY AFFAIRS EXECUTIVE, GREG TORRE, PHD, ESQ, JOINS ELUSYS THERAPEUTICS MANAGEMENT TEAM

Pine Brook, NJ – January 11, 2011 – Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, today announced the appointment of Gregory M. Torre, PhD, ESQ, as Vice President of Regulatory and Quality. Dr. Torre brings nearly 30 years of experience in the global development and commercialization of products in the pharmaceutical and biotechnology industries. Elusys is developing Anthim, an anti-toxin, for the prevention and treatment of anthrax infection following a biowarfare attack.

“Dr. Torre’s experience in overseeing successful regulatory and quality programs adds tremendous depth and expertise to our management team, and he joins the company at an important time in our history,” said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. “Greg has the know-how, perspective and market intelligence to add important insights to our development program, and we welcome his expertise in implementing our regulatory and quality strategies for Anthim.”

Anthrax is a life-threatening infectious disease caused by the bacteria Bacillus anthracis and remains one of the nation’s top biowarfare threats. Inhaled anthrax is often fatal even if treated with antibiotics. Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people.

Dr. Torre has held senior positions with several major pharmaceutical leaders and innovative biotech companies, most recently serving as Vice President, Regulatory Affairs and Quality and Chief Compliance Officer at Alvogen. Prior to that, he was responsible for global regulatory and registration strategies in the therapeutic areas of endocrine/metabolism, gastrointestinal and oncology biologics. Earlier in his career, he managed regulatory affairs for both branded and generic pharmaceutical companies including Bristol-Myers Squib, Sankyo, Watson and Sanofi.
Dr. Torre received a BS in Pharmacy, an MS in Pharmacology/ Toxicology, and a PhD in Pharmacology/Toxicology from St. John’s University, College of Pharmacy, NY. Dr. Torre received his JD from Brooklyn Law School and is a member of the Bar in the State of New Jersey, the District of Columbia and the US Supreme Court.

If all activities in the Elusys development program are completed to the U.S. Food and Drug Administration’s (FDA) satisfaction, the federal government could purchase Anthim for the Strategic National Stockpile under Project BioShield. Project BioShield was established in 2004 to provide much needed funding to procure important countermeasures to protect the American public in the event of a biowarfare attack.

About Anthim

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack.

Anthim has been extensively tested for efficacy and safety in animals and safety in human volunteers. It shows excellent potential as an effective, life-saving, therapeutic for the treatment of people infected by or exposed to anthrax spores. A single dose of Anthim consistently provides a significant increase in survival in anthrax-infected animals.

This project is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201000026C, the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C, and the Department of Defense, under Contract No. W91 13M-10-C-0024.

About Elusys Therapeutics

Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Elusys has been engaged in development of biodefense countermeasures since 2000. The company has established experience in government contract management and to date has received multiple grants and contracts totally up to $177 million in government funding. Anthim, a highly effective, anthrax anti-toxin, is in late-stage development, and is a strong candidate for future procurement into the Strategic National Stockpile. For more information, please visit www.elusys.com.

Regulatory Affairs Executive, Greg Torre, PhD, Esq, Joins Elusys Therapeutics Management Team

www.anthim.com

This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue